ALK and non-small cell lung carcinoma: Although most of the chemoimmunotherapy trials excluded the EGFR and ALK altered NSCLC patients, these groups of patients were evaluated in the IMpower150 study if they have had progression with or unacceptable side effects from treatment with at least one approved tyrosine kinase inhibitor.